FORA Capital LLC Purchases New Stake in Vaxcyte, Inc. (NASDAQ:PCVX)

FORA Capital LLC acquired a new position in Vaxcyte, Inc. (NASDAQ:PCVX) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 34,379 shares of the company’s stock, valued at approximately $3,928,000.

A number of other institutional investors have also recently bought and sold shares of PCVX. China Universal Asset Management Co. Ltd. lifted its position in shares of Vaxcyte by 68.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company’s stock worth $2,453,000 after purchasing an additional 8,685 shares in the last quarter. Harbor Capital Advisors Inc. lifted its position in Vaxcyte by 392.4% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 40,342 shares of the company’s stock worth $3,046,000 after buying an additional 32,149 shares in the last quarter. Tri Locum Partners LP purchased a new stake in Vaxcyte in the 2nd quarter worth approximately $8,559,000. Hsbc Holdings PLC acquired a new stake in shares of Vaxcyte during the 2nd quarter valued at $1,053,000. Finally, Natixis Advisors LLC grew its holdings in shares of Vaxcyte by 61.1% during the 3rd quarter. Natixis Advisors LLC now owns 22,697 shares of the company’s stock valued at $2,594,000 after acquiring an additional 8,606 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Vaxcyte Stock Down 0.3 %

Shares of PCVX stock traded down $0.26 during trading on Wednesday, reaching $91.19. The company had a trading volume of 29,356 shares, compared to its average volume of 903,724. The firm’s 50 day simple moving average is $106.93 and its two-hundred day simple moving average is $89.94. Vaxcyte, Inc. has a one year low of $48.81 and a one year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter last year, the firm earned ($0.91) earnings per share. As a group, research analysts predict that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on PCVX shares. Bank of America increased their price objective on Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Leerink Partners lifted their price target on Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a report on Tuesday, September 3rd. Mizuho increased their price objective on Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th. BTIG Research lifted their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC reissued a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a research report on Wednesday, November 6th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $147.50.

Insider Activity

In other Vaxcyte news, SVP Elvia Cowan sold 5,000 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total value of $538,350.00. Following the sale, the senior vice president now directly owns 12,723 shares in the company, valued at $1,369,885.41. This trade represents a 28.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total transaction of $927,520.00. Following the transaction, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at $10,479,005.02. This represents a 8.13 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 102,464 shares of company stock valued at $11,455,576. 3.10% of the stock is owned by insiders.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.